Results 221 to 230 of about 517,577 (347)

A Mitochondria‐Targeted Nanozyme Platform for Multi‐Pathway Tumor Therapy via Ferroptosis and Cuproptosis Regulation

open access: yesAdvanced Science, EarlyView.
This work reports a mitochondria‐targeted nanozyme platform, MIL‐Cu1.8S‐TPP/FA, which induces potent cuproptosis via localized delivery of Cu1.8S nanodots to mitochondria. Surface‐anchoring these nanodots onto MIL‐88B metal‐organic frameworks enhances both passive and active tumor targeting.
Chenguang Liu   +8 more
wiley   +1 more source

Structure and function of ER membrane contact sites with other organelles

open access: yesNature reviews. Molecular cell biology, 2015
M. J. Phillips, G. Voeltz
semanticscholar   +1 more source

Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer

open access: yesAdvanced Science, EarlyView.
This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan   +6 more
wiley   +1 more source

A liquid-like organelle at the root of motile ciliopathy [PDF]

open access: yes, 2018
Boulgakov, Alexander A   +7 more
core   +1 more source

MTCH2 Deficiency Promotes E2F4/TFRC‐Mediated Ferroptosis and Sensitizes Colorectal Cancer Liver Metastasis to Sorafenib

open access: yesAdvanced Science, EarlyView.
This study identifies MTCH2 as a crucial regulator of ferroptosis in colorectal cancer (CRC) progression. High expression of MTCH2 is correlated with poor prognosis in CRC patients. Furthermore, MTCH2 depletion induces ferroptosis to suppress CRC liver metastasis via the E2F4/TFRC axis and sensitizes tumors to sorafenib treatment, supporting MTCH2 as a
Pu Xing   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy